A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
Public ClinicalTrials.gov record NCT00134147. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents
Study identification
- NCT ID
- NCT00134147
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 1,100 participants
Conditions and interventions
Conditions
Interventions
- Inhaled Insulin Drug
Drug
Eligibility (public fields only)
- Age range
- 35 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2005
- Primary completion
- Not listed
- Completion
- Apr 30, 2007
- Last update posted
- Apr 16, 2008
2005 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | San Diego | California | 92128 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32208 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32209 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Columbus | Georgia | 31904 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66211 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70121 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21230 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28207 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28212 | — |
| Pfizer Investigational Site | Raleigh | North Carolina | 27609 | — |
| Pfizer Investigational Site | Medford | Oregon | 97504-8491 | — |
| Pfizer Investigational Site | Hershey | Pennsylvania | 17033-0850 | — |
| Pfizer Investigational Site | Spartanburg | South Carolina | 29303 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78237 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 103 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00134147, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2008 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00134147 live on ClinicalTrials.gov.